RxDoctor Payments Data

Michael Henry, DPM

Podiatrist · Wilmington, DENPI 1720173057

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 90.5% of the total across 10 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Cardiovascular Systems Inc. at 40.4% of the total. Reporting peaked in 2022 at $148 and has fallen 70.2% since, to $44 in 2025. That places this record below the midpoint for podiatrist clinicians in DE, where the typical reported total is $1,099.

$316in general payments, 2019–2025

Across 10 payments — averaging $31.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cardiovascular Systems Inc.$128
  • AbbVie$35
  • Rikco International, LLC$30
  • Solventum Corporation$27
  • Sandoz$23
  • Averitas Pharma Inc.$23
  • plus $51 from 3 others

What the payments were for

  • Food & beverage$28691%
  • Education$309%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Cardiovascular Systems Inc.1$128
AbbVie2$35
Rikco International, LLC1$30
Solventum Corporation1$27
Sandoz1$23
Averitas Pharma Inc.1$23
Reapplix Inc.1$21
Orthofix Medical, Inc.1$17
Merck1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$316 in reported general payments places this provider in the 25th percentile of 37 podiatrist providers in Delaware.

See all podiatrist providers in Delaware

Medicare billing

Part B allowed, 2024
$228,001
Medicare patients
938
Services billed
3,433

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Ketoconazole66$1,013
Ciclopirox17$616
Doxycycline Hyclate58$483
Ammonium Lactate20$380
Fluocinonide11$209

Paid to pharmacies, not to this prescriber.

Other podiatrist in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →